Neuroprotection by caffeine in hyperoxia-induced neonatal brain injury

International Journal of Molecular Sciences

Volumn 18, Issue 1, 2017, Pages

  Endesfelder, Stefanie ^a   Weichelt, Ulrike ^a   Strauß, Evelyn ^a   Schlör, Anja ^b   Sifringer, Marco ^a   Scheuer, Till ^a   Bührer, Christoph ^a   Schmitz, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF POTSDAM   (Germany)

Author keywords

Anti oxidative response; Caffeine; Developing brain; Hyperoxia; Oxidative stress; Preterm infants

Indexed keywords

APOPTOSIS INDUCING FACTOR; CAFFEINE; CASPASE 3; GELATINASE A; GLUTAMATE CYSTEINE LIGASE; HEME OXYGENASE 1; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR NRF1; ANTIOXIDANT; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; NEUROPROTECTIVE AGENT; OXIDOREDUCTASE; PEROXIREDOXIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HYPEROXIA; LIPID PEROXIDATION; NEUROPROTECTION; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PREMATURITY; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; BRAIN INJURIES; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; APOPTOSIS; BRAIN INJURIES; CAFFEINE; CYTOKINES; GENE EXPRESSION REGULATION; HYPEROXIA; INFLAMMATION; MATRIX METALLOPROTEINASES; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; OXIDOREDUCTASES ACTING ON SULFUR GROUP DONORS; PEROXIREDOXINS; PLASMINOGEN; RATS, WISTAR; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTORS;

EID: 85010049779     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18010187     Document Type: Article

References (80)

1. Marlow, N.; Wolke, D.; Bracewell, M.A.; Samara, M.; Group, E.S. Neurologic and developmental disability at six years of age after extremely preterm birth. N. Engl. J. Med. 2005, 352, 9–19.[CrossRef]][PubMed]
2. Wilson-Costello, D.; Friedman, H.; Minich, N.; Fanaroff, A.A.; Hack, M. Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics 2005, 115, 997–1003.[CrossRef]][PubMed]
3. Volpe, J.J. Perinatal brain injury: From pathogenesis to neuroprotection. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7, 56–64.[CrossRef]]
4. Perrone, S.; Tataranno, M.L.; Stazzoni, G.; Buonocore, G. Biomarkers of oxidative stress in fetal and neonatal diseases. J. Mater. Fetal Neonatal Med. 2012, 25, 2575–2578.[CrossRef]][PubMed]
5. Saugstad, O.D. Update on oxygen radical disease in neonatology. Curr. Opin. Obstet. Gynecol. 2001, 13, 147–153.[CrossRef]][PubMed]
6. Stone, W.L.; Shah, D.; Hollinger, S.M. Retinopathy of prematurity: An oxidative stress neonatal disease. Front. Biosci. 2016, 21, 165–177.[CrossRef]]
7. Buonocore, G.; Perrone, S.; Longini, M.; Vezzosi, P.; Marzocchi, B.; Paffetti, P.; Bracci, R. Oxidative stress in preterm neonates at birth and on the seventh day of life. Pediatr. Res. 2002, 52, 46–49.[CrossRef]][PubMed]
8. Vento, M.; Escobar, J.; Cernada, M.; Escrig, R.; Aguar, M. The use and misuse of oxygen during the neonatal period. Clin. Perinatol. 2012, 39, 165–176.[CrossRef]][PubMed]
9. O’Donovan, D.J.; Fernandes, C.J. Free radicals and diseases in premature infants. Antioxid. Redox Signal. 2004, 6, 169–176.[CrossRef]][PubMed]
10. Lee, Y.S.; Chou, Y.H. Antioxidant profiles in full term and preterm neonates. Chang Gung Med. J. 2005, 28, 846–851. [PubMed]
11. Prasanthi, J.R.; Dasari, B.; Marwarha, G.; Larson, T.; Chen, X.; Geiger, J.D.; Ghribi, O. Caffeine protects against oxidative stress and Alzheimer’s disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic. Biol. Med. 2010, 49, 1212–1220.[CrossRef]][PubMed]
12. Ullah, F.; Ali, T.; Ullah, N.; Kim, M.O. Caffeine prevents d-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain. Neurochem. Int. 2015, 90, 114–124.[CrossRef]][PubMed]
13. Henderson-Smart, D.J.; de Paoli, A.G. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst. Rev. 2010, CD000140.[CrossRef]]
14. Schmidt, B.; Roberts, R.S.; Davis, P.; Doyle, L.W.; Barrington, K.J.; Ohlsson, A.; Solimano, A.; Tin, W. Caffeine therapy for apnea of prematurity. N. Engl. J. Med. 2006, 354, 2112–2121.[CrossRef]][PubMed]
15. Schmidt, B.; Roberts, R.S.; Davis, P.; Doyle, L.W.; Barrington, K.J.; Ohlsson, A.; Solimano, A.; Tin, W. Long-term effects of caffeine therapy for apnea of prematurity. N. Engl. J. Med. 2007, 357, 1893–1902.[CrossRef]][PubMed]
16. Endesfelder, S.; Zaak, I.; Weichelt, U.; Bührer, C.; Schmitz, T. Caffeine protects neuronal cells against injury caused by hyperoxia in the immature brain. Free Radic. Biol. Med. 2014, 67, 221–234.[CrossRef]]
17. Rivkees, S.A.; Wendler, C.C. Adverse and protective influences of adenosine on the newborn and embryo: Implications for preterm white matter injury and embryo protection. Pediatr. Res. 2011, 69, 271–278.[CrossRef]][PubMed]
18. Chavez Valdez, R.; Ahlawat, R.; Wills-Karp, M.; Nathan, A.; Ezell, T.; Gauda, E.B. Correlation between serum caffeine levels and changes in cytokine profile in a cohort of preterm infants. J. Pediatr. 2011, 158, 57–64.[CrossRef]][PubMed]
19. Weichelt, U.; Cay, R.; Schmitz, T.; Strauss, E.; Sifringer, M.; Buhrer, C.; Endesfelder, S. Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine. Eur. Respir. J. 2013, 41, 966–973.[CrossRef]][PubMed]
20. Taha, D.; Kirkby, S.; Nawab, U.; Dysart, K.C.; Genen, L.; Greenspan, J.S.; Aghai, Z.H. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants. J. Mater. Fetal Neonatal Med. 2014, 27, 1698–1702.[CrossRef]][PubMed]
21. Patel, R.M.; Leong, T.; Carlton, D.P.; Vyas-Read, S. Early caffeine therapy and clinical outcomes in extremely preterm infants. J. Perinatol. 2013, 33, 134–140.[CrossRef]][PubMed]
22. Bauer, J.; Maier, K.; Linderkamp, O.; Hentschel, R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics 2001, 107, 660–663.[CrossRef]][PubMed]
23. Steer, P.; Flenady, V.; Shearman, A.; Charles, B.; Gray, P.H.; Henderson-Smart, D.; Bury, G.; Fraser, S.; Hegarty, J.; Rogers, Y. et al. High dose caffeine citrate for extubation of preterm infants: A randomised controlled trial. Arch. Dis. Child. Fetal Neonatal Ed. 2004, 89, F499–F503.[CrossRef]][PubMed]
24. Henderson-Smart, D.J.; Steer, P.A. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst. Rev. 2010, CD000273.[CrossRef]]
25. Shi, X.; Dalal, N.S.; Jain, A.C. Antioxidant behaviour of caffeine: Efficient scavenging of hydroxyl radicals. Food Chem. Toxicol. 1991, 29, 1–6.[CrossRef]]
26. Devasagayam, T.P.; Kamat, J.P.; Mohan, H.; Kesavan, P.C. Caffeine as an antioxidant: Inhibition of lipid peroxidation induced by reactive oxygen species. Biochim. Biophys. Acta 1996, 1282, 63–70.[CrossRef]]
27. Barcelos, R.P.; Souza, M.A.; Amaral, G.P.; Stefanello, S.T.; Bresciani, G.; Fighera, M.R.; Soares, F.A.; Barbosa, N.V. Caffeine supplementation modulates oxidative stress markers in the liver of trained rats. Life Sci. 2014, 96, 40–45.[CrossRef]][PubMed]
28. Tunc, T.; Aydemir, G.; Karaoglu, A.; Cekmez, F.; Kul, M.; Aydinoz, S.; Babacan, O.; Yaman, H.; Sarici, S.U. Toll-like receptor levels and caffeine responsiveness in rat pups during perinatal period. Regul. Pept. 2013, 182, 41–44.[CrossRef]][PubMed]
29. Chavez-Valdez, R.; Wills-Karp, M.; Ahlawat, R.; Cristofalo, E.A.; Nathan, A.; Gauda, E.B. Caffeine modulates TNF-α production by cord blood monocytes: The role of adenosine receptors. Pediatr. Res. 2009, 65, 203–208.[CrossRef]][PubMed]
30. Li, J.; Li, G.; Hu, J.L.; Fu, X.H.; Zeng, Y.J.; Zhou, Y.G.; Xiong, G.; Yang, N.; Dai, S.S.; He, F.T. Chronic or high dose acute caffeine treatment protects mice against oleic acid-induced acute lung injury via an adenosine A2A receptor-independent mechanism. Eur. J. Pharmacol. 2011, 654, 295–303.[CrossRef]][PubMed]
31. Tsutsui, S.; Schnermann, J.; Noorbakhsh, F.; Henry, S.; Yong, V.W.; Winston, B.W.; Warren, K.; Power, C. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J. Neurosci. 2004, 24, 1521–1529.[CrossRef]][PubMed]
32. Ikonomidou, C.; Kaindl, A.M. Neuronal death and oxidative stress in the developing brain. Antioxid. Redox Signal. 2011, 14, 1535–1550.[CrossRef]][PubMed]
33. Chua, C.O.; Vinukonda, G.; Hu, F.; Labinskyy, N.; Zia, M.T.; Pinto, J.; Csiszar, A.; Ungvari, Z.; Ballabh, P. Effect of hyperoxic resuscitation on propensity of germinal matrix haemorrhage and cerebral injury. Neuropathol. Appl. Neurobiol. 2010, 36, 448–458.[CrossRef]][PubMed]
34. Waldbaum, S.; Patel, M. Mitochondrial dysfunction and oxidative stress: A contributing link to acquired epilepsy? J. Bioenerg. Biomembr. 2010, 42, 449–455.[CrossRef]][PubMed]
35. Gozzelino, R.; Jeney, V.; Soares, M.P. Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 323–354.[CrossRef]][PubMed]
36. Ho, E.; Karimi Galougahi, K.; Liu, C.C.; Bhindi, R.; Figtree, G.A. Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol. 2013, 1, 483–491.[CrossRef]][PubMed]
37. Zaghloul, N.; Nasim, M.; Patel, H.; Codipilly, C.; Marambaud, P.; Dewey, S.; Schiffer, W.K.; Ahmed, M. Overexpression of extracellular superoxide dismutase has a protective role against hyperoxia-induced brain injury in neonatal mice. FEBS J. 2012, 279, 871–881.[CrossRef]][PubMed]
38. Sifringer, M.; Brait, D.; Weichelt, U.; Zimmerman, G.; Endesfelder, S.; Brehmer, F.; von Haefen, C.; Friedman, A.; Soreq, H.; Bendix, I. et al. Erythropoietin attenuates hyperoxia-induced oxidative stress in the developing rat brain. Brain Behav. Immun. 2010, 24, 792–799.[CrossRef]][PubMed]
39. Morse, D.; Choi, A.M. Heme oxygenase-1: From bench to bedside. Am. J. Respir. Crit. Care Med. 2005, 172, 660–670.[CrossRef]][PubMed]
40. Bryan, H.K.; Olayanju, A.; Goldring, C.E.; Park, B.K. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem. Pharmacol. 2013, 85, 705–717.[CrossRef]][PubMed]
41. Wu, G.; Fang, Y.Z.; Yang, S.; Lupton, J.R.; Turner, N.D. Glutathione metabolism and its implications for health. J. Nutr. 2004, 134, 489–492. [PubMed]
42. Yang, H.; Magilnick, N.; Lee, C.; Kalmaz, D.; Ou, X.; Chan, J.Y.; Lu, S.C. Nrf1 and Nrf2 regulate rat glutamate-cysteine ligase catalytic subunit transcription indirectly via NF-κB and AP-1. Mol. Cell. Biol. 2005, 25, 5933–5946.[CrossRef]][PubMed]
43. Ma, Q. Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 401–426.[CrossRef]][PubMed]
44. Bendix, I.; Weichelt, U.; Strasser, K.; Serdar, M.; Endesfelder, S.; von Haefen, C.; Heumann, R.; Ehrkamp, A.; Felderhoff-Mueser, U.; Sifringer, M. Hyperoxia changes the balance of the thioredoxin/peroxiredoxin system in the neonatal rat brain. Brain Res. 2012, 1484, 68–75.[CrossRef]][PubMed]
45. Sandberg, M.; Patil, J.; D’Angelo, B.; Weber, S.G.; Mallard, C. NRF2-regulation in brain health and disease: Implication of cerebral inflammation. Neuropharmacology 2014, 79, 298–306.[CrossRef]][PubMed]
46. Esterbauer, H.; Cheeseman, K.H. Determination of aldehydic lipid peroxidation products: Malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990, 186, 407–421. [PubMed]
47. Ahotupa, M.; Mantyla, E.; Peltola, V.; Puntala, A.; Toivonen, H. Pro-oxidant effects of normobaric hyperoxia in rat tissues. Acta Physiol. Scand. 1992, 145, 151–157.[CrossRef]][PubMed]
48. Halliwell, B.; Gutteridge, J.M.C. Free Radicals in Biology and Medicine, 5th ed.; Oxford University Press: Oxford, UK, 2015.
49. Trachootham, D.; Lu, W.; Ogasawara, M.A.; Nilsa, R.D.; Huang, P. Redox regulation of cell survival. Antioxid. Redox Signal. 2008, 10, 1343–1374.[CrossRef]][PubMed]
50. Yadav, S.; Gupta, S.P.; Srivastava, G.; Srivastava, P.K.; Singh, M.P. Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. Neurochem. Res. 2012, 37, 875–884.[CrossRef]][PubMed]
51. Sifringer, M.; von Haefen, C.; Krain, M.; Paeschke, N.; Bendix, I.; Buhrer, C.; Spies, C.D.; Endesfelder, S. Neuroprotective effect of dexmedetomidine on hyperoxia-induced toxicity in the neonatal rat brain. Oxidative Med. Cell. Longev. 2015, 2015, 530371.[CrossRef]][PubMed]
52. Yamada, M.; Kubo, H.; Kobayashi, S.; Ishizawa, K.; Sasaki, H. Interferon-gamma: A key contributor to hyperoxia-induced lung injury in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287, L1042–L1047.[CrossRef]][PubMed]
53. Beckman, J.S.; Koppenol, W.H. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am. J. Physiol. 1996, 271, C1424–C1437. [PubMed]
54. Griscavage, J.M.; Wilk, S.; Ignarro, L.J. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-κB. Proc. Natl. Acad. Sci. USA 1996, 93, 3308–3312.[CrossRef]][PubMed]
55. Hoehn, T.; Felderhoff-Mueser, U.; Maschewski, K.; Stadelmann, C.; Sifringer, M.; Bittigau, P.; Koehne, P.; Hoppenz, M.; Obladen, M.; Buhrer, C. Hyperoxia causes inducible nitric oxide synthase-mediated cellular damage to the immature rat brain. Pediatr. Res. 2003, 54, 179–184.[CrossRef]][PubMed]
56. Ikeno, S.; Nagata, N.; Yoshida, S.; Takahashi, H.; Kigawa, J.; Terakawa, N. Immature brain injury via peroxynitrite production induced by inducible nitric oxide synthase after hypoxia-ischemia in rats. J. Obstet. Gynaecol. Res. 2000, 26, 227–234.[CrossRef]][PubMed]
57. Taoufik, Y.; de Goer de Herve, M.G.; Giron-Michel, J.; Durali, D.; Cazes, E.; Tardieu, M.; Azzarone, B.; Delfraissy, J.F. Human microglial cells express a functional IL-12 receptor and produce IL-12 following IL-12 stimulation. Eur. J. Immunol. 2001, 31, 3228–3239.[CrossRef]]
58. Chang, H.D.; Radbruch, A. The pro- and anti-inflammatory potential of interleukin-12. Ann. N. Y. Acad. Sci. 2007, 1109, 40–46.[CrossRef]][PubMed]
59. Murphy, C.A.; Langrish, C.L.; Chen, Y.; Blumenschein, W.; McClanahan, T.; Kastelein, R.A.; Sedgwick, J.D.; Cua, D.J. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 2003, 198, 1951–1957.[CrossRef]][PubMed]
60. Zeidan-Chulia, F.; Gelain, D.P.; Kolling, E.A.; Rybarczyk-Filho, J.L.; Ambrosi, P.; Terra, S.R.; Pires, A.S.; da Rocha, J.B.; Behr, G.A.; Moreira, J.C. Major components of energy drinks (caffeine, taurine, and guarana) exert cytotoxic effects on human neuronal SH-SY5Y cells by decreasing reactive oxygen species production. Oxidative Med. Cell. Longev. 2013, 2013, 791795.[CrossRef]][PubMed]
61. Leon-Carmona, J.R.; Galano, A. Is caffeine a good scavenger of oxygenated free radicals? J. Phys. Chem. B 2011, 115, 4538–4546.[CrossRef]][PubMed]
62. Tiwari, K.K.; Chu, C.; Couroucli, X.; Moorthy, B.; Lingappan, K. Differential concentration-specific effects of caffeine on cell viability, oxidative stress, and cell cycle in pulmonary oxygen toxicity in vitro. Biochem. Biophys. Res. Commun. 2014, 450, 1345–1350.[CrossRef]][PubMed]
63. Pohanka, M. Caffeine alters oxidative homeostasis in the body of BALB/c mice. Bratislavske Lekarske Listy 2014, 115, 699–703.[CrossRef]][PubMed]
64. Motterlini, R.; Foresti, R.; Bassi, R.; Green, C.J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic. Biol. Med. 2000, 28, 1303–1312.[CrossRef]]
65. Ran, Q.; Liang, H.; Gu, M.; Qi, W.; Walter, C.A.; Roberts, L.J., 2nd; Herman, B.; Richardson, A.; van Remmen, H. Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis. J. Biol. Chem. 2004, 279, 55137–55146.[CrossRef]][PubMed]
66. Schmitz, T.; Krabbe, G.; Weikert, G.; Scheuer, T.; Matheus, F.; Wang, Y.; Mueller, S.; Kettenmann, H.; Matyash, V.; Buhrer, C. et al. Minocycline protects the immature white matter against hyperoxia. Exp. Neurol. 2014, 254, 153–165.[CrossRef]][PubMed]
67. Kilicdag, H.; Daglioglu, Y.K.; Erdogan, S.; Zorludemir, S. Effects of caffeine on neuronal apoptosis in neonatal hypoxic-ischemic brain injury. J. Mater. Fetal Neonatal Med. 2014, 27, 1470–1475.[CrossRef]][PubMed]
68. Geraets, L.; Moonen, H.J.; Wouters, E.F.; Bast, A.; Hageman, G.J. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Biochem. Pharmacol. 2006, 72, 902–910.[CrossRef]][PubMed]
69. Barkett, M.; Gilmore, T.D. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 1999, 18, 6910–6924.[CrossRef]][PubMed]
70. Gu, Y.; Dee, C.M.; Shen, J. Interaction of free radicals, matrix metalloproteinases and caveolin-1 impacts blood-brain barrier permeability. Front. Biosci. 2011, 3, 1216–1231.[CrossRef]]
71. Coutts, A.; Chen, G.; Stephens, N.; Hirst, S.; Douglas, D.; Eichholtz, T.; Khalil, N. Release of biologically active TGF-β from airway smooth muscle cells induces autocrine synthesis of collagen. Am. J. Physiol. Lung Cell Mol. Physiol. 2001, 280, L999–L1008. [PubMed]
72. Millis, A.J.; Hoyle, M.; McCue, H.M.; Martini, H. Differential expression of metalloproteinase and tissue inhibitor of metalloproteinase genes in aged human fibroblasts. Exp. Cell Res. 1992, 201, 373–379.[CrossRef]]
73. Sifringer, M.; Genz, K.; Brait, D.; Brehmer, F.; Lober, R.; Weichelt, U.; Kaindl, A.M.; Gerstner, B.; Felderhoff-Mueser, U. Erythropoietin attenuates hyperoxia-induced cell death by modulation of inflammatory mediators and matrix metalloproteinases. Dev. Neurosci. 2009, 31, 394–402.[CrossRef]][PubMed]
74. Hayakawa, K.; Okazaki, R.; Morioka, K.; Nakamura, K.; Tanaka, S.; Ogata, T. Lipopolysaccharide preconditioning facilitates M2 activation of resident microglia after spinal cord injury. J. Neurosci. Res. 2014, 92, 1647–1658.[CrossRef]][PubMed]
75. Saad, M.A.; Abdelsalam, R.M.; Kenawy, S.A.; Attia, A.S. Ischemic preconditioning and postconditioning alleviates hippocampal tissue damage through abrogation of apoptosis modulated by oxidative stress and inflammation during transient global cerebral ischemia-reperfusion in rats. Chem. Biol. Interact. 2015, 232, 21–29.[CrossRef]][PubMed]
76. Parmar, J.; Jones, N.M. Hypoxic preconditioning can reduce injury-induced inflammatory processes in the neonatal rat brain. Int. J. Dev. Neurosci. 2015, 43, 35–42.[CrossRef]][PubMed]
77. Heusch, G. Cardioprotection: Chances and challenges of its translation to the clinic. Lancet 2013, 381, 166–175.[CrossRef]]
78. Hausenloy, D.J.; Yellon, D.M. Ischaemic conditioning and reperfusion injury. Nat. Rev. Cardiol. 2016, 13, 193–209.[CrossRef]][PubMed]
79. Robertson, N.J.; Tan, S.; Groenendaal, F.; van Bel, F.; Juul, S.E.; Bennet, L.; Derrick, M.; Back, S.A.; Valdez, R.C.; Northington, F. et al. Which neuroprotective agents are ready for bench to bedside translation in the newborn infant? J. Pediatr. 2012, 160, 544–552.[CrossRef]][PubMed]
80. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408.[CrossRef]][PubMed]